Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack - blocking the ...
Both agreed that there have been no trials directly comparing a BsAb therapy vs CAR T cells, so there is no definitive answer, and Landsburg was reluctant to take a hard line on reserving BsAbs until ...
INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20 ... Michael Dickinson, MBBS, FRACP, Lead of the ...
"CAR T cells work well against hematological cancers like leukemia and lymphoma, but they're really not effective for solid tumors ... in ovarian cancer and suggest new avenues to improve the efficacy ...
Three months after the CAR-T cell infusion, the CR rate was 87.5% (7 out of 8). Notably, one patient with leukemia showed a CR with no minimal residual disease (MRD), while another patient with ...